Liwei Deng¹, Henan Sun¹, Jing Wang², Sijuan Huang³, Xin Yang^3,*

CMC-Computers, Materials & Continua, Vol.77, No.2, pp. 2271-2287, 2023, DOI:10.32604/cmc.2023.039062

Abstract In recent years, radiotherapy based only on Magnetic Resonance (MR) images has become a hot spot for radiotherapy planning research in the current medical field. However, functional computed tomography (CT) is still needed for dose calculation in the clinic. Recent deep-learning approaches to synthesized CT images from MR images have raised much research interest, making radiotherapy based only on MR images possible. In this paper, we proposed a novel unsupervised image synthesis framework with registration networks. This paper aims to enforce the constraints between the reconstructed image and the input image by registering the reconstructed image with the input image… More >

ROGHAYEH GHORBANI¹, MAHMOUD GHARBAVI², ALI SHARAFI^3,4, ELHAM RISMANI⁵, HAMED REZAEEJAM⁶, YOUSEF MORTAZAVI^1,*, BEHROOZ JOHARI^3,*

Oncology Research, Vol.32, No.1, pp. 101-125, 2024, DOI:10.32604/or.2023.044741

Abstract In the present study, we investigated the synergistic effects of targeted methotrexate-selenium nanostructure containing Myc decoy oligodeoxynucleotides along with X-irradiation exposure as a combination therapy on LNCaP prostate cancer cells. Myc decoy ODNs were designed based on the promoter of Bcl-2 gene and analyzed by molecular docking and molecular dynamics assays. ODNs were loaded on the synthesized Se@BSA@Chi-MTX nanostructure. The physicochemical characteristics of nanostructures were determined by FTIR, DLS, UV-vis, TEM, EDX, in vitro release, and hemolysis tests. Subsequently, the cytotoxicity properties of them with and without X-irradiation were investigated by uptake, MTT, cell cycle, apoptosis, and scratch assays on… More > Graphic Abstract

SUKRAN SENYUREK¹, SEZER SAGLAM^2,*, ESRA KAYTAN SAGLAM³, HAKAN YANAR⁴, KAAN GOK⁴, DIDEM TASTEKIN⁵, CANAN KOKSAL AKBAS⁶, NERGIZ DAGOGLU SAKIN³, GULBIZ DAGOGLU KARTAL⁷, EMRE BALIK⁸, METIN KESKIN⁴, YASEMIN SANLI⁹, MINE GULLUOGLU¹⁰, ZULEYHA AKGUN¹¹

Oncology Research, Vol.31, No.5, pp. 689-696, 2023, DOI:10.32604/or.2023.030351

Abstract Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with concurrent fluorouracil (5-FU) chemotherapy. The Phase II single-arm KROG 11-02 study using intermediate-course (IC) (33 Gy (Gray)/10 fr (fraction) with concurrent capecitabine) preoperative chemoradiotherapy (CRT) demonstrated a pathologically complete response rate and a sphincter-sparing rate that were close to those of LC-CRT. The current trial aim to compare the pathological/oncological outcomes, toxicity, and quality of life results of LC-CRT and IC-CRT in cases of LARC. The prescribed dose was… More >

OZAN CEM GULER^1,*, EZGI OYMAK², GOZDE YAZICI³, OZLEM OZKAYA AKAGUNDUZ⁴, OGUZ CETINAYAK⁵, PETEK ERPOLAT⁶, ATIL AKSOY⁷, MURSEL DUZOVA⁸, BERNA AKKUS YILDIRIM⁹, MERAL KURT¹⁰, EMINE CANYILMAZ¹¹, GULER YAVAS¹², SERAP AKYUREK¹³, DIDEM COLPAN OKSUZ¹⁴, ESRA KAYTAN SAGLAM¹⁵, OMUR KARAKOYUN CELIK¹⁶, ENIS OZYAR¹⁷, MUSTAFA CENGIZ³, CEM ONAL^1,2,12

Oncology Research, Vol.31, No.3, pp. 299-306, 2023, DOI:10.32604/or.2023.028840

Abstract The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26–87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received… More >

UROS BUMBASIREVIC^1,2,*, MARKO ZIVKOVIC¹, MILOS PETROVIC¹, VESNA CORIC^2,3, NIKOLA LISICIC¹, NEBOJSA BOJANIC^1,2

Oncology Research, Vol.30, No.3, pp. 117-128, 2022, DOI:10.32604/or.2022.027511

Abstract Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with strict follow-up regimens and increased… More >

Annemarie E. M. Post^*†, Johan Bussink^*, Fred C. G. J. Sweep^†, Paul N. Span^*

Oncology Research, Vol.28, No.1, pp. 33-40, 2020, DOI:10.3727/096504019X15555794826018

Abstract Tamoxifen-induced radioresistance, reported in vitro, might pose a problem for patients who receive neoadjuvant tamoxifen treatment and subsequently receive radiotherapy after surgery. Previous studies suggested that DNA damage repair or cell cycle genes are involved, and could therefore be targeted to preclude the occurrence of cross-resistance. We aimed to characterize the observed cross-resistance by investigating gene expression of DNA damage repair genes and cell cycle genes in estrogen receptor-positive MCF-7 breast cancer cells that were cultured to tamoxifen resistance. RNA sequencing was performed, and expression of genes characteristic for several DNA damage repair pathways was investigated, as well as expression… More >

Heming Lu^*†1, Yuying Wu^‡1, Xu Liu^†, Huixian Huang^†, Hailan Jiang^†, Chaohua Zhu^†, Yuping Man^§, Zhaohong Chen^†, Xianfeng Long^†, Qiang Pang^†, Luxing Peng^†, Xianglong Li^†, Junzhao Gu^†, Shan Deng^†, Ligang Xing^*

Oncology Research, Vol.28, No.9, pp. 929-944, 2020, DOI:10.3727/096504021X16318716607908

Abstract This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E arm) or CCRT alone (CCRT arm). All patients received pelvic intensity-modulated radiation therapy (IMRT) and brachytherapy. Weekly cisplatin was administered concurrently with IMRT. Patients in the CCRT+E arm also received concurrent Endostar every 3 weeks for two cycles. The primary endpoint was progression-free survival (PFS) and acute toxicities. The exploratory endpoint was the impact of vascular endothelial growth factor… More >

Chiara Dalle Fratte^*, Silvia Mezzalira^*, Jerry Polesel^†, Elena De Mattia^*, Antonio Palumbo^‡, Angela Buonadonna^§, Elisa Palazzari^¶, Antonino De Paoli^¶, Claudio Belluco^#, Vincenzo Canzonieri^‡** , Giuseppe Toffoli^*, Erika Cecchin^*

Oncology Research, Vol.28, No.9, pp. 847-855, 2020, DOI:10.3727/096504021X16232280278813

Abstract Pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients is related to a favorable prognosis. The identification of early biomarkers predictive of pathological complete response would help optimize the multimodality management of the patients. A panel of 11 tumor-related proteins was investigated by immunohistochemistry in the pretreatment biopsy of a group of locally advanced rectal cancer patients to identify early biomarkers of pathological complete response to neoadjuvant chemoradiotherapy. A mono-institutional retrospective cohort of 95 stage II/III locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy and surgery was selected based on clinical–pathological characteristics and the availability of… More >

YANFEI LI¹, LULU DAI², KE CAI², YINGKUI SONG², XIQING LIU^3,*

BIOCELL, Vol.45, No.3, pp. 685-694, 2021, DOI:10.32604/biocell.2021.013612

Abstract RPA3 (Replication Protein A3) (14 kD) is a part of the canonical heterotrimeric replication protein A complex (RPA/RP-A). This study aimed to explore the functional role of RPA3 and the mechanisms of its dysregulation in breast cancer. Data from the Cancer Genome Atlas (TCGA)-breast cancer patients and GSE75688 were utilized for gene expression and survival analysis. Breast cancer cell lines MDA-MB-231 and SK-BR-3 were used for in-vitro cell studies. Clonogenic assay and immunofluorescent staining of γ-H2AX were performed to examine radiation-induced cytotoxicity. Systemic correlation analysis was performed to identify potential transcription factors (TFs) regulating RPA3 expression. ChIP-qPCR and dual-luciferase assay… More >

YUE CHEN¹, ZHITING TANG², MIAO YU¹, RUI ZHANG^1,*, XINXIN DONG¹, LIANQUN CAO¹

BIOCELL, Vol.44, No.4, pp. 513-524, 2020, DOI:10.32604/biocell.2020.09422

Abstract Preoperative chemoradiation therapy (CRT) is becoming the standard treatment for patients with locally advanced rectal cancer. However, individual differences in response to treatment range from a complete response to complete resistance. Predicting the tumor response to radiotherapy may improve the efficacy of radiotherapy. This review mainly summarizes recent studies about the molecular biomarkers that can predict the response to radiotherapy in rectal cancer. These studies have indicated that the molecular markers involved in the response to radiotherapy mainly include genes related to radiosensitivity, cancer stem cell-related markers, non-coding RNAs (ncRNAs), single-nucleotide polymorphisms (SNPs) and gene methylation, and other factors including… More >